DOCSLIB.ORG

JOURNAL of VIROLOGY VOLUME 59 * SEPTEMBER 1986 * NUMBER 3 Arnold J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
JOURNAL of VIROLOGY VOLUME 59 * SEPTEMBER 1986 * NUMBER 3 Arnold J JOURNAL OF VIROLOGY VOLUME 59 * SEPTEMBER 1986 * NUMBER 3 Arnold J. Levine, Editor in Chief Michael B. A. Oldstone, Editor (1988) (1989) Scripps Clinic & Research Foundation Princeton University La Jolla, Calif. Princeton, N.J. Thomas E. Shenk, Editor (1989) David T. Denhardt, Editor (1987) Princeton University University of Western Ontario Princeton, N.J. London, Ontario, Canada Anna Marie Skalka, Editor (1989) Bernard N. Fields, Editor (1988) Hoffmann-La Roche Inc. Harvard Medical School Nutley, N.J. Boston, Mass. Robert A. Weisberg, Editor (1988) Robert M. Krug, Editor (1987) National Institute of Child Health Sloan-Kettering Institute and Human Development New York, N.Y. Bethesda, Md. EDITORIAL BOARD James Alwine (1988) Hidesaburo Hanafusa (1986) Lois K. Miller (1988) Priscilla A. Schaffer (1987) David Baltimore (1987) William S. Hayward (1987) Peter Model (1986) Sondra Schlesinger (1986) Tamar Ben-Porat (1987) Roger Hendrix (1987) Bernard Moss (1986) Manfred Schubert (1988) Kenneth I. Berns (1988) Martin Hirsch (1986) Fred Murphy (1986) June R. Scott (1986) Michael Botchan (1986) John J. Holland (1987) Opendra Narayan (1988) Bart Sefton (1988) Thomas J. Braciale (1988) Ian H. Holmes (1986) Joseph R. Nevins (1988) Charles J. Sherr (1987) Joan Brugge (1988) Robert W. Honess (1986) Nancy G. Nossal (1987) Silverstein Barrie J. Carter (1987) Nancy Hopkins (1986) Abner Notkins (1986) Saul J. (1988) John M. Coffin (1986) Peter M. Howley (1987) J. Thomas Parsons (1986) Patricia G. Spear (1987) Geoffrey M. Cooper (1987) Alice S. Huang (1987) Ulf G. Pettersson (1986) Nat Sternberg (1986) Donald Court (1987) Steve Hughes (1988) Lennart Philipson (1987) Bruce Stillman (1988) Richard Courtney (1986) Tony Hunter (1986) Lewis I. Pizer (1987) Mark F. Stinski (1986) Clyde S. Crumpacker II Jack D. Keene (1988) Craig R. Pringle (1986) James Strauss (1987) (1988) Thomas J. Kelly, Jr. (1988) Carol Prives (1986) F. William Studier (1987) Thomas Curran (1988) George Khoury (1987) Robert Purcell (1986) Lawrence S. Sturman (1988) Walter Doerfler (1986) Elliott Kieff (1987) R. Frank Ramig (1988) John M. Taylor (1987) Peter Doherty (1986) David Knipe (1988) Fred Rapp (1987) Howard M. Temin (1988) Elvera Ehrenfeld (1986) Daniel Kolakofsky (1986) Dan S. Ray (1986) George F. Vande Woude (1986) Robert N. Eisenman (1988) Michael Lai (1988) Gordon M. Ringold (1987) Inder Verma (1986) Suzanne U. Emerson (1986) Robert Lamb (1988) Harriet Robinson (1988) Edward K. Wagner (1986) Ellen Fanning (1988) Robert A. Lazzarini (1987) William S. Robinson (1986) Raymond M. Welsh, Jr. (1988) Emanuel Faust (1987) Myron Levine (1988) Bernard Roizman (1988) Gail Wertz (1988) S. Jane Flint (1987) Maxine Linial (1988) John K. Rose (1988) Reed B. Wickner (1988) Donald Ganem (1988) Douglas R. Lowy (1986) Naomi Rosenberg (1986) Eckard Wimmer (1988) Costa Georgopolous (1986) Robert Martin (1987) Roland R. Rueckert (1988) Owen Witte (1986) Walter Gerhard (1986) Warren Masker (1987) Norman P. Salzman (1987) Charles Hamish Young (1986) Stephen P. Goff (1988) Thomas Merigan (1986) Joseph Sambrook (1988) Julius S. Youngner (1986) Larry M. Gold (1988) George Miller (1987) Charles E. Samuel (1986) Helen R. Whiteley, Chairman, Publications Board Kirk Jensen, Director of Publications Linda M. Illig, Managing Editor, Journals Judith Nedrow, Production Editor The Journal of Virology (ISSN 0022-538X), a publication of the American Society for Microbiology, 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination offundamental knowledge concerning viruses of bacteria, plants, and animals. Investigators are invited to submit reports of original research in all areas of basic virology, including biochemistry, biophysics, genetics, immunology, morphology, physiology, and pathogenesis and immunity. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Publications Department. The Journal is issued monthly, four volumes per year. The nonmember subscription price is $285 per year; single copies are $21. The member subscription price is $41 (foreign, $54 [surface rate]) per year; single copies are $7.00. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Department, 1913 I St., NW, Washington, DC 20006 (phone: 202 833-9680). Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because offailure to report an address change or for issues "missing from files" will not be allowed. Second-class postage paid at Washington, DC 20006, and at additional mailing offices. POSTMASTER: Send address changes to Journal of Virology, ASM, 1913 I St., NW, Washington, DC 20006. Made in the U.S.A. Copyright © 1986, American Society for Microbiology. E * Vt ,. it jK , E .r ff I'JI- All Rights Reserved. The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the arti- cle may be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, 21 Congress St., Salem, MA 01970, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Author Index Alatossava, Tapani, 551 Enquist, Lynn W., 635 McFarland, Vivian, 628 Shaul, Yosef, 731 Alegre, John N., 669 McMaster, Gary K., 564 Sladek, Todd L., 584 Allaway, Graham P., 768 Faras, Anthony J., 669 Merz, Patricia A., 676 Smith, Rosalind, 535 Arnheiter, Heinz, 751 Fraser, Nigel W., 764 Mora, Peter T., 628 Sodroski, Joseph, 743 Asselin, Claude, 655 Frenkel, Niza, 605 Moss, Jill, 728 Soong, Meei-Meei, 556 Muggeridge, Martin I., 764 Soussi, Thierry, 740 Babinet, Charles, 761 Garcia, Pablo D., 731 Murphy, Cheryl Isaac, 692 Spector, Deborah H., 591 Baksi, Krishna, 628 Gibson, Wade, 703, 714 Spriggs, Melanie K., 646 Bastin, Marcel, 655 Goff, Stephen P., 743 O'Brien, Stephen J., 545 Steele, Paul E., 545 Benko, Donna Mia, 703 Gresser, Ion, 728 Ostrove, Jeffrey M., 660 Straus, Steven E., 660 Bernards, R., 684 Bikel, Ilan, 692 Haseltine, William A., 743 Parrott, Catherine L., 628 Bos, J. L., 684 Hay, John, 660 Parsons, J. Thomas, 755 Tamashiro, Joyce C., 591 Boyce-Jacino, Mike, 669 Hirt, Bernhard, 564 Parsons, Sarah J., 755 Tan, Tse-Hua, 574 Brookes, Sharon, 535 Houweling, A., 684 Peters, Gordon, 535 Tanese, Naoko, 743 Bryan, Theodore, 545 Pfau, Charles, 728 Trautwetter, Annie, 551 Bukowski, Jack F., 735 lijima, Shinji, 556 Placzek, Marysia, 535 Burness, Alfred T. H., 768 Jat, Parmjit S., 746 Rabson, Arnold B., 545 Carp, Richard I., 676 Jochemsen, A. G., 684 Ratiarson, Annick, 655 van der Eb, A. J., 684 Chalifour, Lorraine E., 619 Jongeneel, C. Victor, 564 Raymond, Victoria W., 755 van Kranen, H. J., 684 Chou, Joany, 605 Remenick, James, 660 Vass-Marengo, Judit, 655 Clark, Thomas, 728 Kascsak, Richard J., 676 Resnick, Robert, 669 Collins, Peter L., 646 Kinchington, Paul R., 660 Ritzenthaler, Paul, 551 Cremisi, Chantal, 761 Kozak, Christine, 535 Robakis, Nickolaos K., 676 Wallis, John, 574 Robbins, Alan K., 635 Wang, Lu-Hai, 556 Davis, Nancy L., 751 LeMaster, David M., 759 Roby, Clinton, 714 Wassarman, Paul M., 619 Deiss, Louis P., 605 Levine, Arnold J., 574 Rubenstein, Richard, 676 Watson, Roger J., 635 DePamphilis, Melvin L., 619 Livingston, David M., 692 Rutter, William J., 731 Welsh, Raymond M., 735 Dickson, Clive, 535 Ruyechan, William T., 660 Wertz, Gail W., 751 Diringer, Heino, 676 Maniloff, Jack, 584 Whealy, Mary E., 635 Dunwiddie, Christopher T., Martin, Malcolm A., 545 Sahli, Roland, 564 Wirak, Dana O., 619 669 Mata-Gilsinger, Mireille, 551 Schonberg, Steven, 731 Wisniewski, Henryk M., 676 Dybvig, Kevin, 584 McCarley, Deborah J., 755 Sharp, Phillip A., 746 Woodrow, David, 728 AUTHOR INDEX VOLUME 59 Abe, Mitsuko, 103 Davis, Mark M., 434 Ibanez, Carlos E., 267 Matsubara, Kenichi, 176 Adachi, Akio, 284 Davis, Nancy L., 751 lijima, Shinji, 556 McCarley, Deborah J., 755 Alatossava, Tapani, 551 Deiss, Louis P., 605 lizuka, Hideaki, 242 McFadden, G., 249 Alegre, John N., 669 DeLange, A. M., 249 Ikuta, Kazuyoshi, 154 McFarland, Vivian, 628 Allaway, Graham P., 768 DePamphilis, Melvin L., 619 Imamura, Takayuki, 176 McMaster, Gary K., 564 Andrisani, Ourania, 420 Dickson, Clive, 535 Isfort, R. J., 411 Medina, Daniel, 518 Araki, Masatake, 176 Diringer, Heino, 676 Itin, Ahuva, 301 Merz, David C., 392 Armentrout, Marty A., 216 Donoghue, Daniel J., 292 Ito, Shin-ichi, 103 Merz, Patricia A., 676 Arnheiter, Heinz, 751 Dunwiddie, Christopher T., Iwamoto, S., 112 Milanesi, G., 500 Asselin, Claude, 655 669 Iwasaki, Yuzo, 242 Miyanohara, Atsushi, 176 Auger, Denise, 185 Dybvig, Kevin, 584 Mora, Peter T., 628 Jansen, Hans W., 341 Moran, Patricia A., 506 Babinet, Charles, 761 Eggerding, F., 112 Janssen, Robert S., 1 Mortel, Rodrigue, 369 Babiuk, Lorne A., 401 Endres, Michael J., 1 Jat, Parmjit S., 746 Moscona, Anne, 377 Baczko, Knut, 472 Engers, Howard D., 8 Jenkins, Frank J., 494 Moss, Bernard, 506 Baksi, Krishna, 628
Load more

Recommended publications
  • Enhanced Expression of Vascular Endothelial Growth Factor (VEGF) Plays a Critical Role in the Tumor Progression Potential Induced by Simian Virus 40 Large T Antigen
    Oncogene (2002) 21, 2896 ± 2900 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen Alfonso Catalano1, Mario Romano*,2, Stefano Martinotti3 and Antonio Procopio*,1 1Institute of Experimental Pathology, University of Ancona, Faculty of Medicine, Via Ranieri, 60131 Ancona, Italy; 2Department of Human Pathology, University of Messina, 98125 Messina, Italy; 3Department of Oncology and Neuroscience, `G. D'Annunzio' University, Chieti, Italy Vascular endothelial growth factor (VEGF), an impor- disorders, including mesotheliomas (Kumar-Singh et tant angiogenic factor, regulates cell proliferation, al., 1999). Among these, VEGF, whose crucial role in dierentiation, and apoptosis through activation of its tumor angiogenesis is well established (Hanahan and tyrosine-kinase receptors, such as Flt-1 and Flk-1/Kdr. Folkman., 1996), acts also as a potent mitogen and Human malignant mesothelioma cells (HMC), which survival factor for human malignant mesothelioma have wild-type p53, express VEGF and exhibit cell cells (HMC). In fact, VEGF regulates HMC prolifera- growth increased by VEGF. Here, we demonstrate that tion through its tyrosine-kinase receptors activation early transforming proteins of simian virus (SV) 40, large (i.e. Flt-1 and KDR/¯k-1) (Strizzi et al., 2001). In tumor antigen (Tag) and small tumor antigen (tag), addition, VEGF is the main eector of 5-lipoxygenase which have been associated with mesotheliomas, en- action on HMC survival (Romano et al., 2001). Thus, hanced HMC proliferation by inducing VEGF expres- VEGF plays a key role by regulating multiple sion.
    [Show full text]
  • A Polyoma Mutant That Encodessmall T Antigen but Not Middle T Antigen
    MOLECULAR AND CELLULAR BIOLOGY, Dec. 1984, p. 2774-2783 Vol. 4, No. 12 0270-7306/84/122774-10$02.00/0 Copyright © 1984, American Society for Microbiology A Polyoma Mutant That Encodes Small T Antigen But Not Middle T Antigen Demonstrates Uncoupling of Cell Surface and Cytoskeletal Changes Associated with Cell Transformation T. JAKE LIANG, GORDON G. CARMICHAEL,t AND THOMAS L. BENJAMIN* Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Received 2 July 1984/Accepted 31 August 1984 The hr-t gene of polyoma virus encodes both the small and middle T (tumor) antigens and exerts pleiotropic effects on cells. By mutating the 3' splice site for middle T mRNA, we have constructed a virus mutant, Py8O8A, which fails to express middle T but encodes normal small and large T proteins. The mutant failed to induce morphological transformation or growth in soft agar, but did stimulate postconfluent growth of normal cells. Cells infected by Py8O8A became fully agglutinable by lectins while retaining normal actin cable architecture and normal levels of extracellular fibronectin. These properties of Py8O8A demonstrated the separability of structural changes at the cell surface from those in the cytoskeleton and extracellular matrix, parameters which have heretofore been linked in the action of the hr-t and other viral oncogenes. The early region of polyoma encodes three proteins de- substitution of phenylalanine for tyrosine at position 315 in tected as tumor (T) antigens. These polypeptides of 100,000 middle T has been made and studied in two laboratories, daltons (100K; large T), 56K (middle T), and 22K (small T) with different results.
    [Show full text]
  • Review Article Human Polyomaviruses in Skin Diseases
    SAGE-Hindawi Access to Research Pathology Research International Volume 2011, Article ID 123491, 12 pages doi:10.4061/2011/123491 Review Article Human Polyomaviruses in Skin Diseases Ugo Moens,1 Maria Ludvigsen,1 and Marijke Van Ghelue2 1 Institute of Medical Biology, Faculty of Health Sciences, University of Tromsø, 9037 Tromsø, Norway 2 Department of Medical Genetics, University Hospital of Northern-Norway, 9038 Tromsø, Norway Correspondence should be addressed to Ugo Moens, [email protected] Received 28 February 2011; Accepted 29 June 2011 Academic Editor: Gerardo Ferrara Copyright © 2011 Ugo Moens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Polyomaviruses are a family of small, nonenveloped viruses with a circular double-stranded DNA genome of ∼5,000 base pairs protected by an icosahedral protein structure. So far, members of this family have been identified in birds and mammals. Until 2006, BK virus (BKV), JC virus (JCV), and simian virus 40 (SV40) were the only polyomaviruses known to circulate in the human population. Their occurrence in individuals was mainly confirmed by PCR and the presence of virus-specific antibodies. Using the same methods, lymphotropic polyomavirus, originally isolated in monkeys, was recently shown to be present in healthy individuals although with much lower incidence than BKV, JCV, and SV40. The use of advanced high-throughput sequencing and improved rolling circle amplification techniques have identified the novel human polyomaviruses KI, WU, Merkel cell polyomavirus, HPyV6, HPyV7, trichodysplasia spinulosa-associated polyomavirus, and HPyV9.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0023207 A1 Polansky (43) Pub
    US 20040023207A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0023207 A1 Polansky (43) Pub. Date: Feb. 5, 2004 (54) ASSAYS FOR DRUG DISCOVERY BASED ON Publication Classification MICROCOMPETITION WITH A FOREIGN POLYNUCLEOTIDE (51) Int. Cl." .............................. C12O 1/70; C12O 1/68; C12N 15/85; C12N 15/86 (52) U.S. Cl. .................. 435/5; 435/6; 435/455; 435/456 (76) Inventor: Hanan Polansky, Rochester, NY (US) (57) ABSTRACT Correspondence Address: A recent discovery showed that microcompetition between a Hanan Polansky foreign polynucleotide and a cellular polynucleotide is a risk 3159 S. Winton Rd. factor for Some of the major chronic diseases. The invention Rochester, NY 14623 (US) uses this novel discovery to present assays for Screening compounds based on their effectiveness in modulating Such microcompetition. The effective compounds can be used in (21) Appl. No.: 10/211,295 treatment of these chronic diseases. The invention also presents assays for Screening compounds that can be used in treatment of chronic diseaseS resulting from other foreign (22) Filed: Aug. 1, 2002 polynucleotide-type disruptions. Patent Application Publication Feb. 5, 2004 Sheet 1 of 6 US 2004/0023207 A1 s e 2 9 s H c 2 4 competitor plasmid/test plasmid Figure 1 1 O 09% 1 2 3 4 competitor plasmid/test plasmid -H Ltk- (pSV2Neo) -A-ML (pSV2neo) . A- - - Ltk- (pA1 Oneo) - - - - - - Mill (pA1 Oneo) Figure 2 Patent Application Publication Feb. 5, 2004 Sheet 2 of 6 US 2004/0023207 A1 e 2 r U H c O s S 2 3. Molar ratio (pSV2NeolhMT-ilA-CAT) Figure 3 Patent Application Publication Feb.
    [Show full text]
  • Tumor Antigen (Hybrid Trp-Lac Promoter/Actin Cable Effect) ILAN BIKEL*, THOMAS M
    Proc. NatL Acad. Sci. USA Vol. 80, pp. 906-910, February 1983 Biochemistry Purification of biologically active simian virus 40 small tumor antigen (hybrid trp-lac promoter/actin cable effect) ILAN BIKEL*, THOMAS M. ROBERTS*, MARILUCI T. BLADON*, ROBERT GREEN*, EGON AMANNt, AND DAVID M. LIVINGSTON* *The Sidney Farber Cancer Institute and The Departments of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts 02115; and tDepartment of Biochemistry and Molecular Biology, Harvard University, Cambridge, Massachusetts 02138 Communicated by Morris Friedkin, October 29, 1982 The simian virus 40 small tumor antigen (t antigen) gene has been were grown in L broth containing ampicillin (40 Ag/ml) to an cloned downstream from a hybrid Escherichia coli trp-lac pro- ODW of0.7 and then incubated for 2 hr with 5 mM isopropyl moter anda suitable ribosome binding site. Abacterial clone (865i) f3-D-thiogalactopyranoside. Radiolabeling of proteins with transformed by such a plasmid (pTR865) expresses this gene and, [3S]methionine was performed as described (31). under optimal conditions, can produce .5% ofits total protein as t Antigen and Protein Assays. t antigen was detected by Na- t antigen. Soluble extracts ofsuch a clone were relatively depleted DodSO4/polyacrylamide slab gel electrophoresis (32) using 4% in t antigen, which was found in the initial pellet fraction. The stacking and 15% separating gels. Marker proteins were bovine protein was recovered from this fraction in a significantly purified serum albumin (Mr 68,000), carbonic anhydrase (29,000), form byextraction with urea-containing buffer. After gel filtration concentrations were deter- of such t antigen-enriched solutions, highly purified protein was and myoglobin (17,000).
    [Show full text]
  • PP2A-Dependent Disruption of Centrosome Replication and Cytoskeleton Organization in Drosophila by SV40 Small Tumor Antigen
    Oncogene (2008) 27, 6334–6346 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc ORIGINAL ARTICLE PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen S Kotadia1,LRKao1, SA Comerford2, RT Jones1, RE Hammer3 and TL Megraw1 1Department of Pharmacology, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; 2Department of Molecular Genetics, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA and 3Department of Biochemistry, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA Viruses of the DNA tumor virus family share the ability to cell-cycle and apoptosis regulation, viral oncoproteins transform vertebrate cells through the action of virus- transform cells. Investigation of DNA tumor virus encoded tumor antigens that interfere with normal cell oncoproteins has led to the identification of many physiology. They accomplish this very efficiently by fundamental mechanisms of tumor suppression (Lavia inhibiting endogenous tumor suppressor proteins that et al., 2003; Ahuja et al., 2005). By altering the activity control cell proliferation and apoptosis. Simian virus 40 of p53, retinoblastoma protein and serine/threonine (SV40) encodes two oncoproteins, large tumor antigen, protein phosphatase 2A (PP2A), three key tumor which directly inhibits the tumor suppressors p53 and Rb, suppressors, SV40 can cause tumor formation in and small tumor antigen (ST), which interferes with transgenic mouse models (Ahuja et al., 2005; Arroyo serine/threonine protein phosphatase 2A (PP2A).
    [Show full text]
  • Interactions Between Polyomavirus Large T Antigen and the Viral Replication Origin Dna: How and Why
    INTERACTIONS BETWEEN POLYOMAVIRUS LARGE T ANTIGEN AND THE VIRAL REPLICATION ORIGIN DNA: HOW AND WHY by Yu-Cai Peng Department of Microbiology and Immunology McGill University, Montreal April, 1999 A thesis submitted to the Faculty of Craduate Studies and Re3earch in partial fulfullmeat of the requirements of the degree of doctor of philosophy @Yu-Cai Peng, 1999 National Library Biblioth ue nationale 1+1 of Canada du Cana7 a Acquisitions and Acquisitions et Bibliographie Srvices services bibliographiques 395 Wellmgton Street 395, nie Weliingîm Ottawa ON KIA ON4 OrtawaON K1AON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive Licence ailowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfichelfilm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or othenvise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. TABLE OF CONTENTS Page Tableofcontents................................................... I Abstract .......................................................... VI Resumé........................................................... VI11 Acknowledgements ................................................. X Claim of contribution to kaowledge ................................... XI Listoffigures ...................................................... XllI Guidelines regarding doctoral thesis ................................... XV CHAPTER 1. INTRODUCTION .................................... 1 1. Overview: Life cycle of polyomavirus and simian virus 40 ..........
    [Show full text]
  • Polyoma Virus Small Tumor Antigen Pre-Mrna Splicing Requires Cooperation Between Two 3' Splice Sites Hui GE, JONATHAN NOBLE, JOHN COLGAN, and JAMES L
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 3338-3342, May 1990 Biochemistry Polyoma virus small tumor antigen pre-mRNA splicing requires cooperation between two 3' splice sites Hui GE, JONATHAN NOBLE, JOHN COLGAN, AND JAMES L. MANLEY Department of Biological Sciences, Columbia University, New York, NY 10027 Communicated by Joan A. Steitz, January 25, 1990 (receivedfor review December 13, 1989) ABSTRACT We have studied splicing ofthe polyoma virus proteins also likely play a role in the splicing reaction (e.g., early region pre-mRNA in vitro. This RNA is alternatively refs. 19-22). spliced in vivo to produce mRNA encoding the large, middle- The complexity and size of the splicing apparatus suggests sized (MTAg), and small (StAg) tumor antigens. Our primary that steric constraints may play a role in splicing of some interest was to learn how the 48-nucleotide StAg intron is pre-mRNAs. Consistent with this proposal, several studies excised, because the length of this intron is significantly less have shown that introns in higher eukaryotes have a mini- than the apparent minimum established for mammalian in- mum size requirement. Roughly 45 nucleotides (nt) must trons. Although the products ofall three splices are detected in separate the 5' splice site and branch point (23-27), and the vitro, characterization of the pathway and sequence require- minimum distance between the branch point and 3' splice site ments of StAg splicing suggests that splicing factors interact appears to be approximately 18 nt (26, 28). The simian virus with the precursor RNA in an unexpected way to catalyze 40 small tumor antigen pre-mRNA contains an intron of66 nt removal ofthis intron.
    [Show full text]
  • Drosophila As a Model for Infectious Diseases
    International Journal of Molecular Sciences Review Drosophila as a Model for Infectious Diseases J. Michael Harnish 1,2 , Nichole Link 1,2,3,† and Shinya Yamamoto 1,2,4,5,* 1 Department of Molecular and Human Genetics, Baylor College of Medicine (BCM), Houston, TX 77030, USA; [email protected] (J.M.H.); [email protected] (N.L.) 2 Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, TX 77030, USA 3 Howard Hughes Medical Institute, Houston, TX 77030, USA 4 Department of Neuroscience, BCM, Houston, TX 77030, USA 5 Development, Disease Models and Therapeutics Graduate Program, BCM, Houston, TX 77030, USA * Correspondence: [email protected]; Tel.: +1-832-824-8119 † Current Affiliation: Department of Neurobiology, University of Utah, Salt Lake City, UT 84112, USA. Abstract: The fruit fly, Drosophila melanogaster, has been used to understand fundamental principles of genetics and biology for over a century. Drosophila is now also considered an essential tool to study mechanisms underlying numerous human genetic diseases. In this review, we will discuss how flies can be used to deepen our knowledge of infectious disease mechanisms in vivo. Flies make effective and applicable models for studying host-pathogen interactions thanks to their highly con- served innate immune systems and cellular processes commonly hijacked by pathogens. Drosophila researchers also possess the most powerful, rapid, and versatile tools for genetic manipulation in multicellular organisms. This allows for robust experiments in which specific pathogenic proteins can be expressed either one at a time or in conjunction with each other to dissect the molecular functions of each virulent factor in a cell-type-specific manner.
    [Show full text]
  • Expression of the Hepatitis B Virus X Gene in Mammalian Cells
    Proc. Nati. Acad. Sci. USA Vol. 84, pp. 2513-2517, April 1987 Microbiology Expression of the hepatitis B virus X gene in mammalian cells (in vivo transcription/chloramphenicol acetyltransferase assay/protein analysis/cell fractionation/imnmunofluorescence) ALEEM SIDDIQUI, SHAHID JAMEEL, AND JOHN MAPOLES Department of Microbiology and Immunology, University of Colorado School of Medicine, Denver, CO 80262 Communicated by Theodore T. Puck, December 23, 1986 ABSTRACT The hepatitis B virus (HBV) DNA contains an (National Institutes of Health). Two types of recombinant open reading frame (ORF) designated X, which has the vectors were constructed for X gene expression (Fig. 1B). capacity to encode a protein of 16,560 Da (subtype adw). Such Plasmid pMNX contains an Acc I/Taq I [1076-2020 nucle- a protein has not been identified in either HBV particles or otides (nt)] fragment, which has -300 base pairs (bp) of 5' infected human livers, and therefore its role in the viral life flanking sequences, including the enhancer element (12, 13), cycle remains unknown. We report here the expression of the the X ORF (1380-1842 nt), followed by a polyadenylylation HBV X ORF in cultured cells using recombinant vectors. A signal sequence (1920 nt). This plasmid was designed to protein of 16 kDa was identified by means of an antiserum investigate the possible existence of a promoter upstream of prepared against a synthetic peptide and with human antisera the X region. In plasmid pAdX, the X ORF was placed under from hepatitis B patients as well as those with hepatocellular the control of the adenovirus major late promoter, simian carcinoma.
    [Show full text]
  • Designer Nucleases to Treat Malignant Cancers Driven by Viral Oncogenes Tristan A
    Scott and Morris Virol J (2021) 18:18 https://doi.org/10.1186/s12985-021-01488-1 REVIEW Open Access Designer nucleases to treat malignant cancers driven by viral oncogenes Tristan A. Scott* and Kevin V. Morris Abstract Viral oncogenic transformation of healthy cells into a malignant state is a well-established phenomenon but took decades from the discovery of tumor-associated viruses to their accepted and established roles in oncogenesis. Viruses cause ~ 15% of know cancers and represents a signifcant global health burden. Beyond simply causing cel- lular transformation into a malignant form, a number of these cancers are augmented by a subset of viral factors that signifcantly enhance the tumor phenotype and, in some cases, are locked in a state of oncogenic addiction, and sub- stantial research has elucidated the mechanisms in these cancers providing a rationale for targeted inactivation of the viral components as a treatment strategy. In many of these virus-associated cancers, the prognosis remains extremely poor, and novel drug approaches are urgently needed. Unlike non-specifc small-molecule drug screens or the broad- acting toxic efects of chemo- and radiation therapy, the age of designer nucleases permits a rational approach to inactivating disease-causing targets, allowing for permanent inactivation of viral elements to inhibit tumorigenesis with growing evidence to support their efcacy in this role. Although many challenges remain for the clinical applica- tion of designer nucleases towards viral oncogenes; the uniqueness and clear molecular mechanism of these targets, combined with the distinct advantages of specifc and permanent inactivation by nucleases, argues for their develop- ment as next-generation treatments for this aggressive group of cancers.
    [Show full text]
  • Lentivector-Mediated Transfer of Bmi-1 and Telomerase in Muscle
    UNIVERSITE DE GENEVE FACULTE DES SCIENCES Département de Zoologie et Biologie Animale Professeur Duri RUNGGER ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE FACULTE DES SCIENCES DE LA VIE Laboratoire de Virologie et Génétique Professeur Didier TRONO ________________________________________________________________________________ Lentivector-Mediated Transfer of Bmi-1 and Telomerase in Muscle Satellite Cells Yields a Duchenne Myoblast Cell Line with Long-Term Genotypic and Phenotypic Stability THESE présentée à la Faculté des sciences de l’Université de Genève pour obtenir le grade de Docteur ès sciences, mention biologique par Christophe CUDRE-MAUROUX de Autigny (FR) Thèse N° 3726 Genève Atelier de reproduction d’Uni Mail 1 2006 2 Lentivector-Mediated Transfer of Bmi-1 and Telomerase in Muscle Satellite Cells Yields a Duchenne Myoblast Cell Line with Long-Term Genotypic and Phenotypic Stability 3 Remerciements Je tiens à remercier les diverses personnes qui m'ont aidé pendant cette thèse. Je ne peux les nommer toutes, mais je tiens surtout à exprimer ma profonde gratitude aux personnes suivantes. A mon directeur de thèse, le Prof. Didier Trono. Ses conseils judicieux vont certainement encore résonner dans ma tête pendant longtemps. A mes experts, le Prof. Duri Rungger et le Prof. Joachim Lingner. Je les remercie chaleureusement d’avoir accepté de faire partie de mon jury de thèse. A mes parains de thèse, les Prof. Stylianos Antonarakis et Pierre Spierer. Ils ont été d’une grande aide pendant cette thèse. A tous les membres de mon laboratoire, de mon Département de Génétique et Microbiologie (qui a été renommé Dépatement de Microbiologie et Médecine Moléculaire) et du CMU qui m’ont aidés.
    [Show full text]